CTT Pharma Signs Contract for $3 Million Equity Line of Credit

Core Insights - CTT Pharmaceuticals Holdings, Inc. has signed a contract for a $3 million equity line of credit to fund the manufacturing of its patented technology [1] - The company plans to file an S-1 and become a SEC reporting company [1] - CTT Pharma is awaiting approval or denial from the NIH for clinical trials with Johns Hopkins University [2] Corporate Updates - CTT's submission to the National Science Foundation (NSF) Grant Program is under review, with a funding decision expected by the end of Q4 [3] - The Small Business Association (SBA) is anticipated to notify CTT regarding potential loan approval for manufacturing [3] - CTT's audit for 2024 has been successfully completed by a PCAOB audit firm, marking three years of PCAOB audits [3] - The company's scientists are finalizing a manuscript for submission to a peer-reviewed journal [3]